BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 31023266)

  • 1. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
    Wang R; Gao X; Yu L
    BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.
    Liu WJ; Tan XH; Luo XP; Guo BP; Wei ZJ; Ke Q; He S; Cen H
    Leuk Lymphoma; 2014 Dec; 55(12):2691-8. PubMed ID: 24524305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.
    Mohamed AM; Balsat M; Koering C; Maucort-Boulch D; Boissel N; Payen-Gay L; Cheok M; Mortada H; Auboeuf D; Pinatel C; El-Hamri M; Tigaud I; Hayette S; Dumontet C; Cros E; Flandrin-Gresta P; Nibourel O; Preudhomme C; Thomas X; Nicolini FE; Solly F; Guyotat D; Campos L; Michallet M; Ceraulo A; Mortreux F; Wattel E
    Leuk Res; 2017 May; 56():21-28. PubMed ID: 28167452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical Significance of Truncated Mutant ΔJBP of TET2 Gene in Patients with Acute Myeloid Leukemia].
    Yang YC; Xia T; Luo M; Guo WZ; Zhang LL; Chen XH; Xu ZF; Wang HW; Tan YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1011-1018. PubMed ID: 34362476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.
    Xu Q; Li Y; Lv N; Jing Y; Xu Y; Li Y; Li W; Yao Z; Chen X; Huang S; Wang L; Li Y; Yu L
    Clin Cancer Res; 2017 Aug; 23(15):4511-4522. PubMed ID: 28246275
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical significance of TET2 gene expression in 157 adult acute myeloid leukemia patients with normal cytogenetics].
    Zhu Z; Chen J; Yu M; Chen F; Chen Z; Lou J; Tong H; Huang J; Qian W; Meng H; Jin J
    Zhonghua Xue Ye Xue Za Zhi; 2014 Sep; 35(9):802-7. PubMed ID: 25246247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
    Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
    J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of the Effect of TET2 Mutation and SNP on Clinical Characteristics and Prognosis of AML Patients].
    Li L; An LC; Chu XX; Liu XQ; Wang L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):453-459. PubMed ID: 32319378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.
    Chou WC; Chou SC; Liu CY; Chen CY; Hou HA; Kuo YY; Lee MC; Ko BS; Tang JL; Yao M; Tsay W; Wu SJ; Huang SY; Hsu SC; Chen YC; Chang YC; Kuo YY; Kuo KT; Lee FY; Liu MC; Liu CW; Tseng MH; Huang CF; Tien HF
    Blood; 2011 Oct; 118(14):3803-10. PubMed ID: 21828143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
    Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
    J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Landscape of TET2 mutations in acute myeloid leukemia.
    Weissmann S; Alpermann T; Grossmann V; Kowarsch A; Nadarajah N; Eder C; Dicker F; Fasan A; Haferlach C; Haferlach T; Kern W; Schnittger S; Kohlmann A
    Leukemia; 2012 May; 26(5):934-42. PubMed ID: 22116554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TET2 mutations contribute to adverse prognosis in acute myeloid leukemia (AML): results from a comprehensive analysis of 502 AML cases and the Beat AML public database.
    Pan X; Chang Y; Ruan G; Zhou S; Jiang H; Jiang Q; Huang X; Zhao XS
    Clin Exp Med; 2024 Feb; 24(1):35. PubMed ID: 38349460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tet oncogene family member 2 gene alterations in childhood acute myeloid leukemia.
    Li MJ; Yang YL; Lee NC; Jou ST; Lu MY; Chang HH; Lin KH; Peng CT; Lin DT
    J Formos Med Assoc; 2016 Sep; 115(9):801-6. PubMed ID: 26414667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.
    Cher CY; Leung GM; Au CH; Chan TL; Ma ES; Sim JP; Gill H; Lie AK; Liang R; Wong KF; Siu LL; Tsui CS; So CC; Wong HW; Yip SF; Lee HK; Liu HS; Lau JS; Luk TH; Lau CK; Lin SY; Kwong YL; Leung AY
    Blood Cancer J; 2016 Jul; 6(7):e442. PubMed ID: 27391574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis.
    Wu X; Wang H; Deng J; Zheng X; Ling Y; Gong Y
    Ann Hematol; 2019 Nov; 98(11):2485-2496. PubMed ID: 31482295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysis.
    Tie R; Zhang T; Fu H; Wang L; Wang Y; He Y; Wang B; Zhu N; Fu S; Lai X; Shi J; Huang H
    PLoS One; 2014; 9(6):e93353. PubMed ID: 24936645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of IDH2R140 and IDH2R172 mutations in patients with acute myeloid leukemia: a systematic review and meta-analysis.
    Qin Y; Shen K; Liu T; Ma H
    BMC Cancer; 2023 Jun; 23(1):527. PubMed ID: 37291515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis.
    Li HY; Deng DH; Huang Y; Ye FH; Huang LL; Xiao Q; Zhang B; Ye BB; Lai YR; Mo ZN; Liu ZF
    Eur J Haematol; 2015 May; 94(5):439-48. PubMed ID: 25227715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and Safety of Decitabine Combined with Modified CAG Regimen in Patients Aged ≥ 70 Years with Newly Diagnosed Acute Myeloid Leukemia].
    Cao L; Jiang ZQ; Liu WJ; Sun Q; Zhu Y; Li JY; Qian SX; Hong M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):633-642. PubMed ID: 37356919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.